Who are Dehydroepiandrosterone (DHEA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DHEA (1.0%).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dehydroepiandrosterone-dhea.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dehydroepiandrosterone (DHEA) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dehydroepiandrosterone (DHEA) (Dehydroepiandrosterone (DHEA)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Steroid hormone / Prohormone. Area: Endocrinology, Immunology, Rheumatology.

marketed Steroid hormone / Prohormone Androgen receptor, Estrogen receptor (indirect via peripheral conversion) Endocrinology, Immunology, Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Dehydroepiandrosterone (DHEA) (Dehydroepiandrosterone (DHEA)) — Boston Children's Hospital. DHEA is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating immune function and metabolic processes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dehydroepiandrosterone (DHEA) TARGET	Dehydroepiandrosterone (DHEA)	Boston Children's Hospital	marketed	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (indirect via peripheral conversion)
DHEA (1.0%)	DHEA (1.0%)	EndoCeutics Inc.	phase 3	Steroid hormone / Prohormone	Androgen receptor, Estrogen receptor (via peripheral conversion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Steroid hormone / Prohormone class)

Boston Children's Hospital · 1 drug in this class
EndoCeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dehydroepiandrosterone (DHEA) — Competitive Intelligence Brief. https://druglandscape.com/ci/dehydroepiandrosterone-dhea. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing